España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Merck & Co
MRK
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$97.42
-0.02
-0.02%
Pre-Market: 7:10 PM EDT
Get Report
Comment
Merck & Co (MRK) Forecast
News
Earnings
Merck & Co (MRK) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Merck & Co (NYSE:MRK) Stock
Merck & Co Stock (NYSE: MRK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 20, 2024
Reported Earlier, "J&J, Merck Cut Jobs in Chi...
Benzinga Newsdesk
Tuesday, November 19, 2024
Watching Incyte; Sky News City Editor Mark Kl...
Benzinga Newsdesk
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Vandana Singh
Merck Increases Quarterly Dividend From $0.77...
Benzinga Newsdesk
Merck shares are trading higher after the com...
Benzinga Newsdesk
Merck Reports Topline Results From Pivotal Ph...
Benzinga Newsdesk
Friday, November 15, 2024
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
The Arora Report
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vandana Singh
Merck Says European Medicines Agency's Commit...
Benzinga Newsdesk
Wolfe Research Initiates Coverage On Merck & ...
Benzinga Newsdesk
Thursday, November 14, 2024
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Vandana Singh
Merck Enters Exclusive Global License With La...
Benzinga Newsdesk
Wednesday, November 13, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Tuesday, November 12, 2024
AstraZeneca's High-Level Results From KOMET P...
Benzinga Newsdesk
Merck To Showcase GARDASIL®9 Data At IPVC 202...
Benzinga Newsdesk
Friday, November 08, 2024
Merck Announces That Canada's Drug Agency Has...
Benzinga Newsdesk
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Vandana Singh
Thursday, November 07, 2024
Truist Securities Maintains Buy on Merck & Co...
Benzinga Newsdesk
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Avi Kapoor
Wednesday, November 06, 2024
Guggenheim Maintains Buy on Merck & Co, Lower...
Benzinga Newsdesk
Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom
Avi Kapoor
Monday, November 04, 2024
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Vandana Singh
Friday, November 01, 2024
Wells Fargo Maintains Equal-Weight on Merck &...
Benzinga Newsdesk
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
Vandana Singh
BMO Capital Maintains Outperform on Merck & C...
Benzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Merc...
Benzinga Newsdesk
Thursday, October 31, 2024
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Piero Cingari
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
Vandana Singh
Merck CEO Says Company Expects To Continue To...
Benzinga Newsdesk
Merck Expects 2024 Adjusted EPS Of $7.72-$7.7...
Benzinga Newsdesk
Merck Expects 2024 Sales Of $63.6B-$64.1B Com...
Benzinga Newsdesk
Merck & Co Q3 2024 Adj EPS $1.57 Beats $1.51 ...
Benzinga Newsdesk
Tuesday, October 29, 2024
A Look Into Merck & Co Inc's Price Over Earnings
Benzinga Insights
Monday, October 28, 2024
Why Is Moderna Stock Trading Higher On Monday?
Vandana Singh
Merck And Moderna Initiate INTerpath-009 Phas...
Benzinga Newsdesk
Friday, October 25, 2024
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
Avi Kapoor
Thursday, October 24, 2024
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
Vandana Singh
Merck Says European Commission Approved Two N...
Benzinga Newsdesk
Reported Earlier, CDC Recommends Merck's CAPV...
Benzinga Newsdesk
Wednesday, October 23, 2024
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
Vandana Singh
Tuesday, October 22, 2024
(MRK) - Analyzing Merck & Co's Short Interest
Benzinga Insights
Monday, October 21, 2024
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Vandana Singh
Reported Saturday, Gilead And Merck's Islatra...
Benzinga Newsdesk
Friday, October 18, 2024
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Vandana Singh
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
Vandana Singh
Thursday, October 17, 2024
Merck Reports Data From Planned Interim Analy...
Benzinga Newsdesk
Merck Reports Results From Phase 2b/3 Clinica...
Benzinga Newsdesk
Bernstein Initiates Coverage On Merck & Co wi...
Benzinga Newsdesk
Wednesday, October 16, 2024
Merck Announced Results From Stride-8 Phase T...
Benzinga Newsdesk
Tuesday, October 15, 2024
'Merck Keeps Kinase Inhibitor Options Open As...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch